428 related articles for article (PubMed ID: 12123399)
1. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
[TBL] [Abstract][Full Text] [Related]
2. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
3. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
6. Extended-release niacin for modifying the lipoprotein profile.
Guyton JR
Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
[TBL] [Abstract][Full Text] [Related]
10. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
12. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
[TBL] [Abstract][Full Text] [Related]
18. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
19. Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Yokote K; Niwa K; Hakoda T; Oh F; Kajimoto Y; Fukui T; Kim H; Noda Y; Lundström T; Yajima T
Circ J; 2020 May; 84(6):994-1003. PubMed ID: 32281579
[TBL] [Abstract][Full Text] [Related]
20. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
